Special Issue "Flavivirus Immunotherapy"
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against (re)emerging and Tropical Infections Diseases".
Deadline for manuscript submissions: 31 July 2021.
Interests: Flavivirus; Coronavirus; zoonosis; virus-host interactions; antivirals; vaccines
Special Issues and Collections in MDPI journals
Special Issue in Pharmaceuticals: Current Trends in RNA Virus Vaccines
As the Guest Editor of the Vaccines Special Issue “Flavivirus Immunotheraphy”, I would like to invite you to contribute with an original report, original observation, commentary, or review to it.
As you are perfectly aware, flaviviruses (Flaviviridae family) are arthropod-borne viruses, whose genomes are composed of a single RNA molecule of positive polarity. Flaviviruses are distributed worldwide and many cause diverse clinical conditions, ranging from mild disease to severe hemorrhagic syndromes, neurological complications, and congenital malformations, which can even drive to death. They infect more than 400 million people annually, and may (re)emerge causing epidemics and pandemics. Vaccines are only available for a few flaviviruses and there is no specific therapy on the market for any of them. Thus, a deeper understanding of the immunological mechanisms involved during infection and vaccination is required as, paradoxically, the immune response against these pathogens is crucial to controlling and eliminating infections, but it is also often associated with poor clinical outcomes. Thereby, to achieve a more comprehensive understanding of the current trends in flavivirus immunoprophylaxis, this Special Issue of Vaccines is dedicated to recent scientific and technical progress made in this field. Based on your extensive experience and your recent publications, it would be our honor to publish your work to support the global scientific community. We sincerely hope that you accept our invitation. If you can contribute, please let us know at your earliest convenience, and we will provide you with additional details.
Prof. Dr. Juan Carlos Saiz
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune response